• Alzheimer's disease, the most common form of dementia, has another drug on the list for its treatment. Earlier research has been a failure for decades, but now the Lecanemab drug brings new hope. 

  • Lecanemab, still a drug, has had a small impact on the lives of Alzheimer’s patients, according to the research conducted. The scientists at Alzheimer's Research UK call the finding "momentous."

  • Lecanemab is an antibody that attacks and sticks to beta-amyloid protein, which builds up around the brain cells of people with Alzheimer’s. 

  • The research has found, the drug works in the early stages of the disease. It is found effective in attacking viruses and bacteria, which signals the immune system to clear beta-amyloid from the brain.

  • Earlier drugs were given to manage symptoms and had a primary impact on Alzheimer’s patients. But now research trial of Lecanemab has found that it can actually contribute to treatment. 

  • The discovery is considered a breakthrough event and can prove a turning point in medical history. 

  • Prof. John Hardy, the world’s leading researcher in the treatment of Alzheimer's, says the research was ‘historic’ and ‘optimistic" and that "we're seeing the beginning of Alzheimer's therapies."

Source- BBC News